MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

43.28 +1.04 (+2.46%)
Streaming Delayed Price Updated: 1:38 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
Via AB Newswire
Topics Intellectual Property
News headline image
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Third Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
Maetzold recognized among 586 applicants to The CEO Magazine’s 2025 Executive of the Year Awards — United States program 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Second Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
From Castle Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story